MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1

Bibliographic Details
Main Authors: Gao, C. (Author), Peng, F. H. (Author), Peng, L. K. (Author)
Format: Article
Language:English